DDLSS: Elizabeth Henske "Tuberous Sclerosis, TFEB, and the Target of Rapamycin (mTOR): New Connections"

21.11.2024, 11:00 Uhr

Es liegen keine weiteren Termine für diese Veranstaltung vor.

Aurelio Teleman, B140

Prof Elizabet "Lisa" Henske, Center for LAM Research and Clinical Care at Brigham and Women's Hospital

DDLSS Comittee

englisch

Elizabeth (Lisa) Petri Henske is the Director of the Center for LAM Research and Clinical Care at Brigham and Women's Hospital, Professor of Medicine at Harvard Medical School, an Associate Member of the Broad Institute of MIT and Harvard, and a practicing medical oncologist at the Dana-Farber Cancer Institute. LAM (lymphangioleiomyomatosis) is a destructive lung disease of women leading to lung collapse and respiratory failure, often with rapid progression during pregnancy. Dr. Henske's laboratory made the pivotal discovery that LAM is caused by mutations in the tuberous sclerosis complex 2 (TSC2) gene, leading to clinical trials demonstrating efficacy of mTORC1 inhibitors. Her research laboratory is focused on the cellular, metabolic, and immunologic mechanisms underlying the pathogenesis of tuberous sclerosis complex (TSC) and LAM, supported by multiple grants from the National Institutes of Health. She is a member of the American Society for Clinical Investigation and has received awards for her research from the Tuberous Sclerosis Alliance, The LAM Foundation, the American Thoracic Society, and the Society for Women's Health Research (the Medtronic Prize). EHenske@BWH.Harvard.edu

https://www.dkfz.de/en/distinguished-lecturer/index.html

DKFZ Hörsaal